A Phase 2 interventional study of Pemetrexed 500 mg/m2 and Pemetrexed 1000 mg/m2 in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 16 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-12-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 46th largest by enrollment of the 224 interventional ones that give a count, is one of 3 that started in 2004, is one of 128 in phase 2, and was the 13th registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 48 · Phase 4 8
First in 2001; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 65 across the 224 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 228 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 36th largest by enrollment of the 139 interventional ones that give a count, is one of 8 that started in 2004, is one of 73 in phase 2, and was the 20th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pemetrexed 500 mg/m2
Drug: Pemetrexed 500 mg/m2
Pemetrexed 1000 mg/m2
Drug: Pemetrexed 1000 mg/m2
Drug page: PemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
500 mg/m2, intravenous (IV), every 21 days, one year from registration date
Also known as: Alimta, LY231514
Drug page: PemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
Also known as: Alimta, LY231514
Best Overall Response
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria as determined by the Case Judgment Committee. Best overall response was defined as the most favorable overall response recorded for each patient during the observation period. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (up to 3.2 years)
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression.
Time frame: time of response to progressive disease (up to 3.2 years)
Progression-Free Survival (PFS)
PFS was defined as time from the scheduled date of the first treatment cycle until the date of confirmation of progressive disease on the overall response rating. For patients who died before confirmation of progressive disease, the number of days until the date of death (from any cause) was handled as progression-free survival.
Time frame: baseline to measured progressive disease (up to 3.2 years)
Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)
20-items assessed quality of life in patients undergoing chemotherapy. Scores range from 1 (not at all/very poor) to 5 (very much/very well). Face scale scores (patient circles number of the face that best fits his/her feelings) range from 1 (sad face) to 5 (smiling face). Item scores were grouped according to Functional (daily activity: 5 items), Physical (5 items), Emotional (psychological condition: 4 items), Social Attitude (5 items), and Face Scale (1 item). Score of subscales were converted to scores with range from 0 to 100. Higher scores represent higher QOL.
Time frame: Baseline (pre-dose), 3 Months after first dose of Cycle 1
Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS)
FACT-L LCS measured health-related quality of life (HR-QL) related to additional concerns of lung cancer. Original LCS subscale scores range from 0 to 28, but the scores were converted to scores with a range of 0 to 100 in this study. Higher scores represent better HR-QL.
Time frame: Baseline (pre-dose), 3 Months after first dose of Cycle 1
| Milestone | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 |
|---|---|---|
| Started | 114 | 112 |
| Safety analysis population | 114 | 111 |
| Full analysis set population | 108 | 108 |
| Completed | 0 | 0 |
| Not completed | 114 | 112 |
| Withdrew: Entry criteria exclusion | 2 | 0 |
| Withdrew: Treated with another systemic agent | 1 | 1 |
| Withdrew: Adverse event | 11 | 21 |
| Withdrew: Progressive disease | 84 | 72 |
| Withdrew: Toxicity after dose reduction | 7 | 8 |
| Withdrew: Family/caregiver decision | 5 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Good clinical practice violation | 0 | 1 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria as determined by the Case Judgment Committee. Best overall response was defined as the most favorable overall response recorded for each patient during the observation period. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 |
|---|---|---|
| Complete Response (CR) | 0 | 0 |
| Partial Response (PR) | 20 | 16 |
| Stable Disease (SD) | 40 | 34 |
| Progressive Disease (PD) | 48 | 58 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression.
| months | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 |
|---|---|---|
| Duration of Response | 4.9 (3.8 to 8.7) | 3.0 (2.8 to 6.1) |
PFS was defined as time from the scheduled date of the first treatment cycle until the date of confirmation of progressive disease on the overall response rating. For patients who died before confirmation of progressive disease, the number of days until the date of death (from any cause) was handled as progression-free survival.
| months | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 |
|---|---|---|
| Progression-Free Survival (PFS) | 3.0 (2.0 to 3.5) | 2.5 (1.8 to 3.2) |
20-items assessed quality of life in patients undergoing chemotherapy. Scores range from 1 (not at all/very poor) to 5 (very much/very well). Face scale scores (patient circles number of the face that best fits his/her feelings) range from 1 (sad face) to 5 (smiling face). Item scores were grouped according to Functional (daily activity: 5 items), Physical (5 items), Emotional (psychological condition: 4 items), Social Attitude (5 items), and Face Scale (1 item). Score of subscales were converted to scores with range from 0 to 100. Higher scores represent higher QOL.
| units on a scale | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 |
|---|---|---|
| Functional Baseline (n=107, n=107) | 77.0 ± 24.81 | 75.0 ± 26.18 |
| Functional Change from Baseline (n=58, n=60) | -1.5 ± 23.66 | -3.7 ± 19.99 |
| Physical Baseline (n=107, n=107) | 78.9 ± 18.02 | 73.9 ± 21.06 |
| Physical Change from Baseline (n=58, n=60) | -1.6 ± 18.27 | -3.5 ± 17.21 |
| Emotional Baseline (n=107, n=107) | 67.2 ± 20.21 | 62.1 ± 23.29 |
| Emotional Change from Baseline (n=58, n=60) | -1.7 ± 17.36 | 0.3 ± 20.10 |
| Sociality Baseline (n=107, n=107) | 45.9 ± 22.09 | 46.1 ± 22.37 |
| Sociality Change from Baseline (n=58, n=60) | 1.6 ± 12.26 | 1.6 ± 17.05 |
| Face Scale Baseline (n=107, n=107) | 59.3 ± 20.75 | 59.3 ± 25.12 |
| Face Scale Change from Baseline (n=58, n=60) | -1.3 ± 20.64 | -2.1 ± 21.73 |
FACT-L LCS measured health-related quality of life (HR-QL) related to additional concerns of lung cancer. Original LCS subscale scores range from 0 to 28, but the scores were converted to scores with a range of 0 to 100 in this study. Higher scores represent better HR-QL.
| units on a scale | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 |
|---|---|---|
| Baseline (n=107, n=107) | 71.5 ± 18.81 | 69.6 ± 18.52 |
| Change from Baseline (n=58, n=60) | 3.0 ± 16.13 | 0.4 ± 18.63 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed 500 mg/m2 | — | 19/114 (16.7%) | 114/114 (100%) |
| Pemetrexed 1000 mg/m2 | — | 21/111 (18.9%) | 111/111 (100%) |
| Event | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 |
|---|---|---|
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 6/114 | 3/111 |
| PyrexiaGeneral disorders | 0/114 | 5/111 |
| PneumoniaInfections and infestations | 1/114 | 2/111 |
| Haemoglobin decreasedInvestigations | 0/114 | 2/111 |
| AnorexiaMetabolism and nutrition disorders | 0/114 | 2/111 |
| RashSkin and subcutaneous tissue disorders | 0/114 | 2/111 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/114 | 1/111 |
| Vertigo positionalEar and labyrinth disorders | 1/114 | 1/111 |
| DiarrhoeaGastrointestinal disorders | 1/114 | 1/111 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/114 | 1/111 |
| Event | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 |
|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 88/114 | 88/111 |
| RashSkin and subcutaneous tissue disorders | 79/114 | 87/111 |
| Alanine aminotransferase increasedInvestigations | 81/114 | 82/111 |
| White blood cell count decreasedInvestigations | 80/114 | 81/111 |
| AnorexiaMetabolism and nutrition disorders | 56/114 | 76/111 |
| Neutrophil count decreasedInvestigations | 73/114 | 74/111 |
| Blood lactate dehydrogenase increasedInvestigations | 71/114 | 71/111 |
| Haemoglobin decreasedInvestigations | 59/114 | 68/111 |
| NauseaGastrointestinal disorders | 64/114 | 64/111 |
| Lymphocyte count decreasedInvestigations | 56/114 | 64/111 |
| Age Continuous(years) | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 | Total |
|---|---|---|---|
| Mean | 60.8 ± 8.7 | 61.3 ± 8.8 | 61.1 ± 8.7 |
| Sex: Female, Male(Participants) | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 | Total |
|---|---|---|---|
| Female | 40 | 39 | 79 |
| Male | 68 | 69 | 137 |
| Region of Enrollment(participants) | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 | Total |
|---|---|---|---|
| Japan | 108 | 108 | 216 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 | Total |
|---|---|---|---|
| 0 - Fully Active | 43 | 36 | 79 |
| 1 - Ambulatory, Restricted Strenuous Activity | 59 | 66 | 125 |
| 2 - Ambulatory, No Work Activities | 6 | 6 | 12 |
| Histological Types(participants) | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 | Total |
|---|---|---|---|
| Adenocarcinoma | 77 | 80 | 157 |
| Squamous Cell Carcinoma | 23 | 25 | 48 |
| Large Cell Carcinoma | 5 | 1 | 6 |
| Adenosquamous Carcinoma | 1 | 0 | 1 |
| Other | 2 | 2 | 4 |
| Height(centimeters (cm)) | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 | Total |
|---|---|---|---|
| Mean | 161.0 ± 7.9 | 161.1 ± 8.7 | 161.0 ± 8.3 |
| Weight(kilograms) | Pemetrexed 500 mg/m2 | Pemetrexed 1000 mg/m2 | Total |
|---|---|---|---|
| Mean | 59.8 ± 9.9 | 59.1 ± 11.9 | 59.5 ± 10.9 |
The record gives a start of Oct 2004, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →